Bioxytran receives CDSCO approval for first-in-human ProLectin-I trial

BIOXYTRAN, INC

India's CDSCO granted IND authorization (CT-06, No. CT/ND/03/2023) to evaluate ProLectin-I injection.
Trial will assess safety, tolerability, PK/PD; results to guide Phase II in Long COVID and IPF.
Separate approval from prior ProLectin-M authorization (Dec 2, 2022).
ProLectin-I targets viral persistence and fibrosis; Long COVID affects 65-100 million worldwide.
Trial at each site requires ethics committee approval before initiation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.